Sigma Planning Corp Has $165,000 Stock Position in Aptose Biosciences Inc. (NASDAQ:APTO)

Sigma Planning Corp increased its stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the period. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing.

Separately, Armistice Capital LLC bought a new position in Aptose Biosciences during the second quarter worth about $1,300,000. 26.62% of the stock is owned by institutional investors and hedge funds.

Aptose Biosciences Stock Down 5.3 %

Shares of APTO stock opened at $0.36 on Monday. The firm has a market capitalization of $6.61 million, a price-to-earnings ratio of -0.12 and a beta of 1.26. Aptose Biosciences Inc. has a 12-month low of $0.33 and a 12-month high of $2.91. The firm has a fifty day moving average of $0.38 and a 200-day moving average of $0.63.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on Aptose Biosciences in a research note on Wednesday, November 13th. They issued a “hold” rating for the company.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.